Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.68 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 5/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615383 | 1.00 | PRCP (0.68) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL496387 | 1.00 | PRCP (0.68) | PRCPDPP7TLR2HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL4320225 | 0.98 | PRCP (0.66) | PRCPDPP7TLR2HTR2CHTR2B | |
| Acetic Acid SCHEMBL2183483 | 0.94 | PRCP (0.62) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL13990631 | 0.94 | PRCP (0.61) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL13359247 | 0.94 | PRCP (0.61) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL4710537 | 0.94 | PRCP (0.61) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL22019454 | 0.90 | PRCP (0.57) | PRCPDPP7TLR2HTR2CHTR2B | |
| SCHEMBL23169303 | 0.90 | — | — | |
| Trifluoroacetic Acid SCHEMBL3332141 | 0.88 | PRCP (0.56) | PRCPDPP7TLR2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939658-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20200270221-A1 | ANALGESIC COMPOUNDS | KTHERA, LLC | 2020-08-27 | — | — | US | disclosed |
| WO-2019195720-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-3283480-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017046606-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2016166186-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | WO | disclosed |
| US-20140113005-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-24 | — | — | US | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| EP-1874739-B1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | VCAM1, ICAM1, CD69 | PRCP 2639/4885DPP7 1825/4885TLR2 568/4885 |
| US-20200270221-A1 | ANALGESIC COMPOUNDS | INA, IK, ACHE | PRCP 4163/4885DPP7 4479/4885TLR2 2858/4885 |
| US-20140113005-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK2, CHEK1 | PRCP 2827/4885DPP7 3797/4885TLR2 3721/4885 |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK2, CHEK1 | PRCP 2827/4885DPP7 3797/4885TLR2 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.